Is lipoprotein(a) an independent causal risk factor for atherosclerotic cardiovascular disease?

Lipoprotein(a) [Lp(a)] is a highly specialized, atherogenic lipoprotein whose circulating concentrations are over 90% genetically determined. Evidence from extensive genetic, observational, and mechanistic studies confirms its role as a key driver of cardiovascular risk.

Clinical and genetic evidence for causality

• Established Independence: Large prospective cohorts, such as the Women’s Health Study and BiomarCaRE, along with multivariable Mendelian randomization analyses, demonstrate that elevated Lp(a) is an independent, causal risk factor for atherosclerotic cardiovascular disease (ASCVD).
• Risk Thresholds: Cardiovascular risk rises significantly when Lp(a) concentrations exceed the clinical threshold of 50 mg/dL (or 125 nmol/L). This risk persists independently of traditional risk factors, even when low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B levels are aggressively lowered.

Mechanistic pathways of pathogenicity

• Pro-atherogenic Signaling: Lp(a) acts as the primary vehicle for bioactive oxidized phospholipids (OxPLs) in human plasma. Upon entering the arterial intima, these OxPLs activate scavenger and pattern-recognition receptors (including TLR2/4, CD36, and LOX-1), triggering NF-κB inflammatory cascades. This pathway upregulates adhesion molecules (VCAM-1, ICAM-1) and chemokines (MCP-1, IL-8), accelerating monocyte recruitment and macrophage foam-cell formation.
• Pro-thrombotic and Calcific Actions: OxPLs generate local oxidative stress, lower nitric oxide bioavailability, and impair endothelial barrier function. Additionally, the apo(a) component of Lp(a) shares high structural homology with plasminogen, allowing it to competitively inhibit fibrinolysis and promote thrombosis. Beyond ASCVD, elevated Lp(a) and its OxPL cargo promote osteogenic phenotypes in valvular cells, causally driving calcific aortic valve disease (CAVD).

Bottom line

• Lipoprotein(a) is an independent, genetically determined causal risk factor for ASCVD and valvular calcification, driving vascular pathology through a synergistic combination of OxPL-mediated inflammation, endothelial dysfunction, and impaired fibrinolysis.